Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman/Hatch patent reform

Executive Summary

Sen. Hatch (R-Utah) has asked representatives from the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and the Generic Pharmaceutical Industry Association to meet with him Nov. 17 to discuss potential revisions to the Waxman/Hatch patent reform legislation of 1984

You may also be interested in...



BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics

BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS035067

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel